ACAAI 2019

In a post hoc analysis of the LIBERTY ASTHMA QUEST study, researchers found that dupilumab may reduce exacerbations in patients with allergic bronchopulmonary aspergillosis.

Asthma plus atopic dermatitis may lead to poorer sleep-specific outcomes in pediatric patients.

Ragweed sublingual immunotherapy tablet improved symptoms and decreased the need for rescue medication in the largest allergy immunotherapy trial in children with ragweed allergic rhinitis with or without conjunctivitis.

Among patients with severe asthma, benralizumab treatment improved nasal symptoms, which worsen with increasing baseline blood eosinophil count.

The majority of patients with cystic fibrosis experience at least 1 antibiotic adverse drug reaction.

This article is part of MPR‘s coverage of the ACAAI 2019 meeting, taking place in Houston, TX. Our staff will report on medical research related to allergies, asthma, and more conducted by experts in the field. Check back regularly for more news from ACAAI 2019. Data from the open-label extension (OLE) portion of the phase…

Fractional exhaled nitric oxide values may help in the identification of cough variant asthma in patients with chronic cough.

Mepolizumab was associated with reductions in eosinophil levels and asthma exacerbations,
as well as improvements in quality of life in uncontrolled severe eosinophilic asthma.

In a real-world setting, mepolizumab therapy significantly reduced the rate of asthma exacerbations and their related costs.

Budesonide oral suspension was associated with improvements in dysphagia in patients with eosinophilic esophagitis.